US Patent

US10758549 — Compositions of obeticholic acid and methods of use

Method of Use · Assigned to Intercept Pharmaceuticals Inc · Expires 2036-04-26 · 10y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compositions of obeticholic acid, including Ocaliva, and methods of using them to treat various diseases and conditions.

USPTO Abstract

The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.

Drugs covered by this patent

Ocaliva (OBETICHOLIC ACID) · Intercept Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2945`	—	Ocaliva
`U-2945`	—	Ocaliva

Patent Metadata

Patent number: US10758549
Jurisdiction: US
Classification: Method of Use
Expires: 2036-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Intercept Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.